Albion Financial Group’s Novo Nordisk NVO Stock Holding History

Albion Financial Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.9K	Sell	353 -30	-8%	-$1.29K	﹤0.01%	386
2026 Q1	$14.1K	Buy	383 +30	+8%	+$1.42K	﹤0.01%	378
2025 Q4	$18K	Hold	353	–	–	﹤0.01%	353
2025 Q3	$19.6K	Hold	353	–	–	﹤0.01%	336
2025 Q2	$24.4K	Hold	353	–	–	﹤0.01%	296
2025 Q1	$24.5K	Sell	353 -154	-30%	-$12.7K	﹤0.01%	294
2024 Q4	$43.6K	Buy	507 +278	+121%	+$30.1K	﹤0.01%	262
2024 Q3	$27.3K	Buy	229 +30	+15%	+$4K	﹤0.01%	273
2024 Q2	$28.4K	Hold	199	–	–	﹤0.01%	267
2024 Q1	$25.6K	Hold	199	–	–	﹤0.01%	263
2023 Q4	$20.6K	Buy	+199	New	+$19.7K	﹤0.01%	270
2022 Q3	–	Sell	-36	Closed	-$2K	–	530
2022 Q2	$2K	Hold	36	–	–	﹤0.01%	422
2022 Q1	$2K	Sell	36 -36	-50%	-$1.85K	﹤0.01%	479
2021 Q4	$4K	Buy	+72	New	+$3.9K	﹤0.01%	465

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Albion Financial Group's NVO Position: Q2 2026 in Review

Albion Financial Group reduced its Novo Nordisk (NVO) stake by 7.8% in Q2 2026, selling an estimated $1.29K and leaving 353 shares worth $16.9K. The position accounts for ﹤0.01% of the portfolio, ranked #386.

Albion Financial Group first reported a position in NVO in Q4 2021 and has held it in 14 quarters since. The position peaked at $43.6K in Q4 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Albion Financial Group held 353 shares of Novo Nordisk worth $16.9K as of Q2 2026.
Albion Financial Group sold 30 Novo Nordisk shares in Q2 2026, an estimated $1.29K.
Novo Nordisk made up ﹤0.01% of Albion Financial Group's portfolio in Q2 2026, its #386 holding.
Albion Financial Group first reported a position in Novo Nordisk in Q4 2021 and has held it in 14 quarters since.
Albion Financial Group's Novo Nordisk position peaked at $43.6K in Q4 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Albion Financial Group's 13F filing for Q2 2026, filed 22 Jul 2026.